结直肠癌
预测标记
医学
肿瘤科
癌
内科学
免疫组织化学
细胞凋亡
新辅助治疗
病态的
放化疗
癌症研究
癌症
病理
生物
乳腺癌
生物化学
作者
Hee Jin Chang,Kyung Hae Jung,Dae Yong Kim,Seung‐Yong Jeong,Hyo Seong Choi,Young Hoon Kim,Dae Kyung Sohn,Byong Chul Yoo,Sun Mi Lim,Dae-Hyun Kim
标识
DOI:10.1016/j.humpath.2005.01.018
摘要
In an attempt to improve local control and survival in patients with advanced rectal carcinoma, neoadjuvant chemoradiation therapy (CRT) has been increasingly used in patient management. However, a significant proportion of patients shows poor response to adjuvant CRT. Thus, the ability to predict CRT responsiveness in patients with rectal cancer would benefit effective management. Several molecular markers related to regulation of cell cycle, apoptosis, or DNA repair have been proposed as candidate predictors of therapeutic response to CRT, but, to date, none has been definitively proven to be predictive of CRT response. To evaluate the use of various molecular markers as predictors of the response to CRT in rectal carcinoma, we investigated immunohistochemical expressions of p53, p21 WAF1/CIP1 , Bcl-2, Bax, Ki-67, Ku-70, and 2 new candidate markers (histone deacetylase 1 and metabotropic glutamate receptor 4) in pretreatment biopsy samples of 130 rectal carcinomas. We further compared the expressions of these molecular markers with the pathological responses of the tumors after therapy. We found that Bax expression, among the markers studied, was exclusively related to tumor regression. Its expression was significantly higher in the complete response group as compared with the partial response group (54% versus 29%, P = .017). This result confirms that apoptosis plays an important role in tumor response to CRT and provides evidence that Bax may serve as a predictable molecular marker for chemoradiosensitivity in rectal carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI